# US 2022/0403438 A1 · Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0403438 A1
- Document ID: US20220403438A1
- Status: Published application
- Kind: A1
- Application number: 17/767,361
- Filed: 2020-10-08
- Published: 2022-12-22
- Earliest claimed: 2019-10-08
- Assignees: The Trustees of Boston College
- Applicants: Trustees of Boston College
- Inventors: Yunan Zheng; James Sebastian Italia; Abhishek Chatterjee
- Web page: https://patentgrep.com/patent/US20220403438A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 14/47: from mammals
- C12N 9/93: {Ligases (6)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/67: General methods for enhancing the expression
- C12Y 601/01001: Tyrosine-tRNA ligase (6.1.1.1)
- C12Y 601/01002: Tryptophan-tRNA ligase (6.1.1.2)
- C12Y 601/01004: Leucine--tRNA ligase (6.1.1.4)
- C12Y 601/01026: Pyrrolysine-tRNAPyl ligase (6.1.1.26)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates generally to methods of producing a protein comprising a first unnatural amino acid (UAA) and a second, different UAA, and proteins comprising a first UAA and a second, different UAA.

## Claims

### Claim 1

A method of producing a protein comprising a first unnatural amino acid (UAA) and a second, different UAA, the method comprising culturing a mammalian cell with:
(i) a nucleic acid comprising a nucleotide sequence encoding a first tRNA comprising an anticodon that hybridizes to a first codon selected from UAG, UGA, and UAA, and is capable of being charged with the first UAA;
(ii) a nucleic acid comprising a nucleotide sequence encoding a first aminoacyl-tRNA synthetase capable of charging the first tRNA with the first UAA;
(iii) a nucleic acid comprising a nucleotide sequence encoding a second tRNA comprising an anticodon that hybridizes to a second codon selected from UAG, UGA, and UAA, and is capable of being charged with the second UAA, wherein the first and second tRNA do not contain the same anticodon;
(iv) a nucleic acid comprising a nucleotide sequence encoding a second aminoacyl-tRNA synthetase capable of charging the second tRNA with the second UAA; and
(v) a nucleic acid comprising a nucleotide sequence encoding the protein comprising the first codon and the second codon;
under conditions that permit the first tRNA, when expressed in the cell and charged with the first UAA, to hybridize to the first codon and direct the incorporation of the first UAA into the protein, and the second tRNA, when expressed in the cell and charged with the second UAA, to hybridize to the second codon and direct the incorporation of the second UAA into the protein;
wherein the amount of the protein comprising the first and second UAA expressed by the cell is at least 10% of the amount of a reference protein expressed by the same cell or a similar cell, wherein the reference protein is an otherwise identical protein that does not comprise the first and second UAA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first tRNA is an analog or derivative of a prokaryotic tryptophanyl-tRNA.

### Claim 3 (depends on 2)

The method of claim 2, wherein the prokaryotic tryptophanyl-tRNA is an E. coli tryptophanyl-tRNA.

### Claim 4 (depends on 3)

The method of claim 3, wherein the first tRNA comprises a nucleotide sequence selected from any one of SEQ ID NOs: 49-54 or 108-113.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first aminoacyl-tRNA synthetase is an analog or derivative of a prokaryotic tryptophanyl-tRNA synthetase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the prokaryotic tryptophanyl-tRNA synthetase is an E. coli tryptophanyl-tRNA synthetase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the first aminoacyl-tRNA synthetase comprises an amino acid sequence selected from any one of SEQ ID NOs: 44-48.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first codon is UGA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first UAA is a tryptophan analog.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first UAA is selected from 5-HTP and 5-AzW.

### Claim 11 (depends on 1)

The method of claim 1, wherein the second tRNA is an analog or derivative of a prokaryotic leucyl-tRNA.

### Claim 12 (depends on 11)

The method of claim 11, wherein the prokaryotic leucyl-tRNA is an E. coli leucyl-tRNA.

### Claim 13 (depends on 12)

The method of claim 12, wherein the second tRNA comprises a nucleotide sequence selected from any one of SEQ ID NOs: 16-43.

### Claim 14 (depends on 1)

The method of claim 1, wherein the second aminoacyl-tRNA synthetase is an analog or derivative of a prokaryotic leucyl-tRNA synthetase.

### Claim 15 (depends on 14)

The method of claim 14, wherein the prokaryotic leucyl-tRNA synthetase is an E. coli leucyl-tRNA synthetase.

### Claim 16 (depends on 15)

The method of claim 15, wherein the second aminoacyl-tRNA synthetase comprises an amino acid sequence selected from any one of SEQ ID NOs: 1-15.

### Claim 17 (depends on 1)

The method of claim 1, wherein the second codon is UAG.

### Claim 18 (depends on 1)

The method of claim 1, wherein the second UAA is a leucine analog.

### Claim 19 (depends on 18)

The method of claim 18, wherein the second UAA is selected from LCA and Cys-5-N3.

### Claim 20 (depends on 1)

The method of claim 1, wherein the second tRNA is an analog or derivative of a prokaryotic tyrosyl-tRNA.

### Claim 21 (depends on 20)

The method of claim 20, wherein the prokaryotic tyrosyl-tRNA is an E. coli tyrosyl-tRNA.

### Claim 22 (depends on 21)

The method of claim 21, wherein the second tRNA comprises a nucleotide sequence selected from any one of SEQ ID NOs: 68-69 or 104-105.

### Claim 23 (depends on 20)

The method of claim 20, wherein the second aminoacyl-tRNA synthetase is an analog or derivative of a prokaryotic tyrosyl-tRNA synthetase.

### Claim 24 (depends on 23)

The method of claim 23, wherein the prokaryotic tyrosyl-tRNA synthetase is an E. coli tyrosyl-tRNA synthetase.

### Claim 25 (depends on 24)

The method of claim 24, wherein the second aminoacyl-tRNA synthetase comprises the amino acid sequence of SEQ ID NO. 70.

### Claim 26 (depends on 20)

The method of claim 20, wherein the second codon is UAG.

### Claim 27 (depends on 20)

The method of claim 20, wherein the second UAA is a tyrosine analog.

### Claim 28 (depends on 27)

The method of claim 27, wherein the second UAA is selected from OmeY, AzF, and OpropY.

### Claim 29 (depends on 1)

The method of claim 1, wherein the second tRNA is an analog or derivative of an archael pyrrolysyl-tRNA.

### Claim 30 (depends on 29)

The method of claim 29, wherein the archael pyrrolysyl-tRNA is an M. barkeri pyrrolysyl-tRNA.

### Claim 31 (depends on 30)

The method of claim 30, wherein the second tRNA comprises a nucleotide sequence selected from any one of SEQ ID NOs: 72-100 or 106-107.

### Claim 32 (depends on 29)

The method of claim 29, wherein the second aminoacyl-tRNA synthetase is an analog or derivative of an archael pyrrolysyl-tRNA synthetase.

### Claim 33 (depends on 32)

The method of claim 32, wherein the archael pyrrolysyl-tRNA synthetase is an M. barkeri pyrrolysyl-tRNA synthetase.

### Claim 34 (depends on 33)

The method of claim 33, wherein the second aminoacyl-tRNA synthetase comprises the amino acid sequence of SEQ ID NO: 101.

### Claim 35 (depends on 29)

The method of claim 29, wherein the second codon is UAG.

### Claim 36 (depends on 29)

The method of claim 29, wherein the second UAA is a pyrrolysine analog.

### Claim 37 (depends on 36)

The method of claim 36, wherein the second UAA is selected from BocK, CpK, and AzK.

### Claim 38 (depends on 1)

The method of claim 1, wherein the amount of protein comprising the first and second UAA expressed by the cell is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the amount of the reference protein expressed by the same cell or a similar cell.

### Claim 39 (depends on 1)

The method of claim 1, wherein the reference protein comprises a wild-type amino acid residue at the positions corresponding to the first and second UAA.

### Claim 40 (depends on 1)

The method of claim 1, wherein the protein is an antibody (or a fragment thereof, e.g., an antigen-binding fragment thereof), bispecific antibody, nanobody, affibody, viral protein, chemokine, cytokine, antigen, blood coagulation factor, hormone, growth factor, enzyme, cell signaling protein, or any other polypeptide or protein.

### Claim 41 (depends on 40)

The method of claim 40, wherein the protein is an antibody (or a fragment thereof, e.g., an antigen-binding fragment thereof).

### Claim 42 (depends on 1)

The method of claim 1, wherein the cell is a human cell.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cell is a human embryonic kidney (HEK) or a Chinese hamster ovary (CHO) cell.

### Claim 44 (depends on 1)

The method of claim 1, further comprising purifying the protein.

### Claim 45 (depends on 1)

The method of claim 1, further comprising chemically modifying the first UAA.

### Claim 46 (depends on 1)

The method of claim 1, further comprising chemically modifying the second UAA.

### Claim 47 (depends on 46)

The method of claim 46, wherein the chemical modification comprises conjugation to a detectable label or molecule.

### Claim 48 (depends on 47)

The method of claim 47, wherein the molecule is a drug (e.g., a small molecule drug).

### Claim 49 (depends on 47)

The method of claim 47, wherein the detectable label or molecule coupled to the protein via the first UAA is different from the detectable label or molecule coupled to the protein via the second UAA.

### Claim 50

A method of producing a protein comprising a tryptophan analog and a leucine analog, the method comprising culturing a mammalian cell with:
(i) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA comprising an anticodon that hybridizes to a UGA codon, and is capable of being charged with the tryptophan analog;
(ii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA synthetase capable of charging the derivative of the E. coli tryptophanyl-tRNA with the tryptophan analog;
(iii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli leucyl-tRNA comprising an anticodon that hybridizes to UAG codon, and is capable of being charged with the leucine analog;
(iv) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli leucyl-tRNA synthetase capable of charging the derivative of the E. coli leucyl-tRNA with the leucine analog; and
(v) a nucleic acid comprising a nucleotide sequence encoding the protein comprising the UGA codon and the UAG codon;
under conditions that permit the derivative of the E. coli tryptophanyl-tRNA, when expressed in the cell and charged with the tryptophan analog, to hybridize to the UGA codon and direct the incorporation of the tryptophan into the protein, and the derivative of the E. coli leucyl-tRNA, when expressed in the cell and charged with the leucine analog, to hybridize to the UAG codon and direct the incorporation of the leucine analog into the protein.

### Claim 51

A method of producing a protein comprising a tryptophan analog and a tyrosine analog, the method comprising culturing a mammalian cell with:
(i) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA comprising an anticodon that hybridizes to a UGA codon, and is capable of being charged with the tryptophan analog;
(ii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA synthetase capable of charging the derivative of the E. coli tryptophanyl-tRNA with the tryptophan analog;
(iii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tyrosyl-tRNA comprising an anticodon that hybridizes to UAG codon, and is capable of being charged with the tyrosine analog;
(iv) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tyrosyl-tRNA synthetase capable of charging the derivative of the E. coli tyrosyl-tRNA with the tyrosine analog; and
(v) a nucleic acid comprising a nucleotide sequence encoding the protein comprising the UGA codon and the UAG codon;
under conditions that permit the derivative of the E. coli tryptophanyl-tRNA, when expressed in the cell and charged with the tryptophan analog, to hybridize to the UGA codon and direct the incorporation of the tryptophan into the protein, and the derivative of the E. coli tyrosyl-tRNA, when expressed in the cell and charged with the tyrosine analog, to hybridize to the UAG codon and direct the incorporation of the tyrosine analog into the protein.

### Claim 52

A method of producing a protein comprising a tryptophan analog and a pyrrolysine analog, the method comprising culturing a mammalian cell with:
(i) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA comprising an anticodon that hybridizes to a UGA codon, and is capable of being charged with the tryptophan analog;
(ii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an E. coli tryptophanyl-tRNA synthetase capable of charging the derivative of the E. coli tryptophanyl-tRNA with the tryptophan analog;
(iii) a nucleic acid comprising a nucleotide sequence encoding a derivative of an M. barkeri pyrrolysyl-tRNA comprising an anticodon that hybridizes to UAG codon, and is capable of being charged with the pyrrolysine analog,
(iv) a nucleic acid comprising a nucleotide sequence encoding a derivative of an M. barkeri pyrrolysyl-tRNA synthetase capable of charging the derivative of the M. barkeri pyrrolysyl-tRNA with the pyrrolysine analog; and
(v) a nucleic acid comprising a nucleotide sequence encoding the protein comprising the UGA codon and the UAG codon;
under conditions that permit the derivative of the E. coli tryptophanyl-tRNA, when expressed in the cell and charged with the tryptophan analog, to hybridize to the UGA codon and direct the incorporation of the tryptophan into the protein, and the derivative of the E. coli pyrrolysyl-tRNA, when expressed in the cell and charged with the pyrrolysine analog, to hybridize to the UAG codon and direct the incorporation of the pyrrolysine analog into the protein.

### Claim 53 (depends on 1)

A protein comprising a first unnatural amino acid (UAA) and a second UAA produced by the method of claim 1.

### Claim 54

A protein expressed in a mammalian cell comprising a first unnatural amino acid (UAA) that is a tryptophan analog and a second UAA that is a leucine analog.

### Claim 55 (depends on 54)

The protein of claim 54, wherein the tryptophan analog is selected from 5-HTP and 5-AzW.

### Claim 56 (depends on 54)

The protein of claim 54, wherein the leucine analog is selected from LCA and Cys-5-N3.

### Claim 57

A protein expressed in a mammalian cell comprising a first unnatural amino acid (UAA) that is tryptophan analog and a second UAA that is tyrosine analog.

### Claim 58 (depends on 57)

The protein of claim 57, wherein the tryptophan analog is selected from 5-HTP and 5-AzW.

### Claim 59 (depends on 57)

The protein of claim 57, wherein the tyrosine analog is selected from OmeY, AzF, and OpropY.

### Claim 60

A protein expressed in a mammalian cell comprising a first unnatural amino acid (UAA) that is a tryptophan analog and a second UAA that is a pyrrolysine analog.

### Claim 61 (depends on 60)

The protein of claim 60, wherein the tryptophan analog is selected from 5-HTP and 5-AzW.

### Claim 62 (depends on 60)

The protein of claim 60, wherein the pyrrolysine analog is selected from BocK, CpK, AzK, and CpK.

### Claim 63 (depends on 53)

The protein of claim 53, wherein a detectable label or molecule is covalently coupled to the protein via the first UAA.

### Claim 64 (depends on 53)

The protein of claim 53, wherein a detectable label or molecule is covalently coupled to the protein via the second UAA.

### Claim 65 (depends on 64)

The protein of claim 64, wherein the detectable label or molecule coupled to the protein via the first UAA is different from the detectable label or molecule coupled to the protein via the second UAA.

### Claim 66 (depends on 53)

The protein of claim 53, wherein the protein is an antibody (or a fragment thereof, e.g., an antigen-binding fragment thereof), bispecific antibody, nanobody, affibody, viral protein, chemokine, cytokine, antigen, blood coagulation factor, hormone, growth factor, enzyme, cell signaling protein, or any other polypeptide or protein.

### Claim 67 (depends on 66)

The protein of claim 66, wherein the protein is an antibody (or a fragment thereof, e.g., an antigen-binding fragment thereof).
